ROJ Login Register My Manuscripts
Instructions for Authors
The Radiation Oncology Journal (ROJ) is a peer-reviewed publication of the Korean Society for Radiation Oncology. The ROJ is published quarterly on the last day of March, June, September, and December, one volume per year. Any physicians or researchers throughout the world can submit a manuscript if the scope of the manuscript is appropriate. Articles in the following categories will be published: original articles, invited review articles, case reports, editorials, and letters to the Editor related to basic or clinical radiation oncology.
Manuscripts for submission to ROJ should be prepared according to the following instructions. ROJ follows the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (http://www.icmje.org/urm_main.html), commonly known as "the Vancouver style," if not otherwise described below.
1. RESEARCH AND PUBLICATION ETHICS
2. ELECTRONIC SUBMISSION OF MANUSCRIPT
3. PEER REVIEW PROCESS
4. MANUSCRIPT PREPARATION
5. COMMUNICATIONS TO THE PUBLISHER
6. ADDITIONAL INFORMATION
1. RESEARCH AND PUBLICATION ETHICS
For the research and publication ethics policies not stated on this site, Good Publication Practice Guidelines for Medical Journals or Guidelines on Good Publication can be applied.
(1) Journal policies on authorship and contributorship
1) Authorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these four conditions. For any persons who do not meet the above four criteria, they may be placed as contributors in the Acknowledgments section. Description of co-first authors or co-corresponding authors is also accepted if the corresponding author believes that their roles are equally contributed. After the initial submission of a manuscript, any changes in authorship must be explained by a letter to the Editor-in-Chief from the authors concerned. This letter must be signed by all authors of the paper. Copyright transfer and conflict of interest disclosure forms must be completed by every author. ROJ does not correct authorship after publication unless a mistake has been made by the editorial staff.

2) Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the editorial board. Submitted manuscripts are screened for possible duplicate publication by Similarity Check upon arrival. If duplicate publication related to the papers of this journal is detected, the authors will be announced in the journal, and their institutes will be informed, and there will also be penalties for the authors.

3) Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. ROJ maintains a zero-tolerance policy when addressing allegations of plagiarism, duplicate publication (self-publication), data falsification, and scientific misconduct. Articles will be retracted if ethics violations are substantiated. Plagiarism is defined by the World Association for Medical Editors (WAME) as the "use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission and presenting them as new and original rather than derived from an existing source." ROJ participates in the Crosscheck/iThenticate program to investigate incidents of possible plagiarism. Manipulating data through fabrication, omission, or intentional distortion is unacceptable. Authors should be prepared to provide original data to editors if there is a question of authenticity. Claims of scientific misconduct are investigated and addressed, guided by the Committee of Publication Ethics (COPE) Code of Conduct.
(2) Statement of Informed Consent and Institutional Review Board Approval
Authors should have obtained written informed consent from all participants prior to inclusion in the study, and copies of written informed consent should be kept for studies on human subjects. For clinical studies of human subjects, a certificate, agreement, or approval by the Institutional Review Board (IRB) of the author’s institution is required. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.
The statement should be included in the Materials and Methods section after the IRB approval. Identifying details of the participants should not be published in written descriptions and photographs. In cases where identifying details are essential for scientific purposes, the participant should have given written informed consent for the identifying information to be published, and it should be stated separately.
Waiver of the informed consent can only be granted by the appropriate IRB and/or national research ethics committee in compliance with the current laws of the country in which the study was performed, and this should be separately stated. It should be noted that manuscripts that do not contain statements on IRB approval and patient informed consent can be returned to the authors before the review process.
(3) Statement of Human and Animal Rights
All studies on human subjects must be conducted according to the principles expressed in the World Medical Association Declaration of Helsinki. Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. The name or initials of the patient should not be displayed, and the patient’s identity should not be known when submitting photographs related to the patient. If there is a possibility that the patient’s identity may be exposed, it should be stated that the patient has given written consent.
All studies involving animals must state that the guidelines for the use and care of laboratory animals of the authors’ institution, or any national law, were followed.
All studies dealing with clinical trials should be registered on the primary national clinical trial registration site, such as Korea Clinical Research Information Service (CRiS, http://cris.nih.go.kr), other primary national registry sites accredited by World Health Organization or ClinicalTrials.gov (http://clinicaltrials.gov), a service of the US National Institutes of Health.
(4) How the journal will handle complaints and appeals
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board of ROJ will discuss the suspected cases and reach a decision. ROJ will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
(5) Journal policies on conflicts of interest/competing interests
Conflict of interest exists when an author or the author’s institution, reviewer, or editor has financial or personal relationships that inappropriately influence or bias their actions. Such relationships are also known as dual commitments, competing interests, or competing loyalties. These relationships vary from being negligible to having great potential to influence judgment. Not all relationships represent true conflict of interest. On the other hand, the potential for conflict of interest can exist regardless of whether an individual believes that the relationship affects their scientific judgment. Financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, or the science itself. Conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion (http://www.icmje.org/conflicts-of-interest/). If there are any conflicts of interest, the authors should disclose them in the manuscript. The conflicts of interest may occur during the research process as well; however, it is important to provide disclosure. If there is a disclosure, editors, reviewers, and reader can approach the manuscript after understanding the situation and background for the completed research. The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data.
(6) Journal policies on data sharing and reproducibility
1) Open data policy
For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data or waiver of data sharing, authors should contact the editorial office.

2) Clinical data sharing policy
This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019, must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record. All the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
(7) Journal's policy on ethical oversight
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
The Research Ethics Committee of the Korean Society for Radiation Oncology covers ethical issues involved with research and publication. This committee is composed of one chairperson and the members of the committee. The director of the ethics committee acts as the chairperson of this committee. The members of the Research Ethics Committee include the vice president, the auditor, the directors of general affairs, research, and publication committees, and two directors without a portfolio of the society become ex officio. The members of this committee serve for a term of two years, and they may be reappointed.
If presented with convincing evidence of dual publication, fragmentation, plagiarism, fabrication, or theft of intellectual property in journals, the committee meeting will be held immediately for investigation. If evidence becomes available that the regulation has been breached, publication of the corresponding manuscript is immediately canceled and all authors, including the corresponding author, are banned from any publication in the ROJ published for the next three years. The investigation results of the committee meeting must be notified for immediate disciplinary measures and reported to the board of directors. Other issues that are not specified in this regulation abide by the decisions made by board members of the society, which conform with the Ethics Code of Science Technology set forth by the Korean Federation of Science Technology Societies.
(8) Journal's policy on intellectual property
All published papers become the permanent property of the Korean Society for Radiation Oncology. Copyrights of all published materials are owned by the Korean Society for Radiation Oncology.
(9) Journal's options for post-publication discussions and corrections
The post-publication discussion is available through a letter to the editor. If any readers have a concern on any articles published, they can submit a letter to the editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.
(10) Journal’s policy on preprint
A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer-reviewed scholarly journal. ROJ allows authors to submit the preprint to the journal. It is not treated as duplicate submission or duplicate publication. ROJ recommends authors to disclose it with DOI in the letter to the editor during the submission process. Otherwise, it may be screened from the plagiarism check program — Similarity Check (Crosscheck). Preprint submission will be processed through the same peer-review process as a usual submission. If the preprint is accepted for publication, authors are recommended to update the information at the preprint with a link to the published article in ROJ, including DOI at ROJ. It is strongly recommended that authors cite the article in ROJ instead of the preprint at their next submission to journals.
2. ELECTRONIC SUBMISSION OF MANUSCRIPT
Manuscript submission is only available through the online submission site at https://submit.e-roj.org. Submission instructions are available on the website. All articles submitted to the ROJ must comply with these instructions. Failure to do so will result in the return of the manuscript and a possible delay in publication. For assistance, please contact us via E-mail (rojeditor@gmail.com), telephone (+82-2-743-6574).
3. PEER REVIEW PROCESS
The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. Original Articles are generally reviewed at least by two peer reviewers. The Editor-in-Chief is responsible for final decisions regarding the acceptance of a peer-reviewed paper. An initial decision will normally be made within four weeks of receiving a manuscript, and the reviewers’ comments are sent to the corresponding authors by E-mail. Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate the alterations that have been made in response to the referees’ comments item by item. Failure to resubmit the revised manuscript within 12 weeks of the editorial decision is regarded as a withdrawal.
4. MANUSCRIPT PREPARATION
(1) General Guideline
Authors are required to submit their manuscripts after reading the following instructions. Any manuscript that does not conform to the following requirements will be considered inappropriate and may be returned. When a manuscript is received for consideration, the editors assume that no similar paper has been or will be submitted for publication elsewhere. The main document with manuscript text and tables should be prepared with an MS-word program
  • The manuscript should be written in 11-point font with double-line spacing on A4-sized (21.0×29.7 cm) paper with 25 mm margins on the top, bottom, right and left.
  • All manuscript pages are to be numbered at the middle of the bottom consecutively.
  • (2) Language
    Manuscripts must be written succinctly in clear, grammatical English. All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer. Medical terminology should be written based on the most recent edition of Dorland’s Illustrated Medical Dictionary or the most recent edition of English-Korean Korean-English Medical Terminology, published by the Korean Medical Association. The use of acronyms and abbreviations is discouraged and should be kept to a minimum. When used, they are to be defined where first used, followed by the acronym or abbreviation in parentheses. Drug and chemical names should be stated in standard chemical or generic nomenclature. Units of measure should be presented according to the SI units (e.g., Gy, Sv, Bq, m, kg, L).
    (3) Reporting Guidelines for Specific Study Designs
    For the specific study design, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table.
    Initiative Type of study Source
    CONSORT Randomized controlled trials http://www.consort-statement.org
    STARD Studies of diagnostic accuracy http://www.stard-statement.org
    PRISMA Preferred reporting items of systematic reviews and meta-analyses http://www.prisma-statement.org
    STROBE Observational studies in epidemiology http://www.strobe-statement.org
    ORIGINAL ARTICLES
    Original articles are reports of basic or clinical investigations. The manuscript for an original article should be organized on a separate page in the following sequence: title page, abstract and keywords, text (introduction, materials and methods, results, discussion, and conclusion), statements, references, tables, and figure legends.

    1) Title page
    The title Page should carry the following information.
  • The title should be short, informative, and contain the major keywords (no more than 15 words). It is not necessary to lead with expressions like "clinical research on -" or "the study on -."
  • Each author's name (first name, middle name, and surname) followed by the highest academic degree (e.g., Gil Dong Hong, MD).
  • The name of the department (s) and institution (s) where the work was conducted. If the authors' affiliation is different, indicate individual departments and institutions by inserting a superscript letter immediately after the author's name, and the same letter in front of the appropriate institution.
  • Running title of fewer than 60 characters.
  • Source(s) of support in the form of grants, equipment, drugs, or all of these.
  • Complete mailing address, telephone, and E-mail for correspondence and reprints.

  • 2) Abstract and Keywords
    The abstract should be no more than 250 words, and described concisely, in a paragraph, Purpose, Materials and Methods, Results, and Conclusion. Up to six keywords should be listed below the abstract. For selecting keywords, refer to the Medical Subject Headings; if suitable MeSH terms are not yet available for recently introduced terms, present terms may be used.

    3) Text
    Text should be arranged in the following order: Introduction, Materials and Methods, Results, Discussion, and Conclusion.

    Introduction
    Introduction section should contain 1) the background and rationale of the study and 2) the objective of the study. The former part should state background information and references that inform the reader as to why the study was performed. Please avoid an extensive review of the literature. The final paragraph of the introduction should clearly state the hypothesis and the objective of the study.

    Materials and Methods
    Materials and Methods section should include sufficient details of the research design, subjects, and methods. Sufficient details need to be addressed in the methodology section of an experimental study so that it can be further replicated by others. The sources of special chemicals or reagents should be given along with the source location (name of the company, city, state/province, and country). Identify and provide references for all the statistical methods used. Statistical methods should be described meticulously. Software used for the statistical analysis should be stated with the name, manufacturer, and version. For studies using human subjects, the detail of IRB approval and patient informed consent should be stated. For animal experiments, a statement of approval by the institutional animal care committee or appropriate substitute should be provided.

    Results
    Present the results in logical sequence in the text, along with tables and figures. Do not repeat data that are already covered in the tables and/or figures; summarize only important observations. Do not illustrate minor details if their message is adequately conveyed by simple descriptive text. Make sure to give results for all items evaluated as mentioned in Materials and Methods section. State the statistical significance of the results.

    Discussion and Conclusion
    Emphasize the advances in knowledge provided by the study and the conclusions that follow from them. Do not repeat in detail the data given in the Results section. Include in the Discussion the implications of the findings and their limitations. Relate the observations to other relevant studies. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not supported by the data.

    4) Statements
    All manuscripts must contain the following statements after the main text and before the reference list.

    Statement of Ethics
    In the manuscript, the authors should state that subjects have given their written informed consent and that the study protocol was approved by the institute’s committee on human research.
    • (1) Study approval statement: Provide name and affiliation of the committee who approved the study and the decision reference number like as “This study protocol was reviewed and approved by [committee name, affiliation, and approval number].” If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be stated, including the name of the ethics committee who made that decision.
    • (2) Consent to participate statement: For studies using human subjects, state whether written informed consent was obtained from participants to participate in the study. If written informed consent was not required, or if the study has been granted an exemption from requiring written informed consent, this should also be stated, including the name of the ethics committee who made that decision.

    Conflicts of Interest Statement
    All potential conflicts of interest must be stated within the text of the manuscript, under this heading. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations. Also, the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. Please state "The authors have no conflicts of interest to declare" if no conflicts exist.

    Acknowledgement (optional)
    If necessary, persons who have made substantial contributions, but who have not met the criteria for authorship, are acknowledged here. An exception is where funding was provided, which should be included in Financial Support.

    Financial Support
    Authors must give full details about the funding of any research relevant to the study, including the name of the funding agency, country and the number of the grant provided by the funding agency.

    Author Contributions
    In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfil the ICMJE criteria for authorship should be credited in the Acknowledgement section.

    Data Availability Statement
    Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers, and readers without unnecessary restriction wherever possible. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data.
    Examples of Data Availability Statements:
    · The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
    · Publicly available datasets were used in this study. These can be found in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
    · All data generated or analyzed during this study are included in this article [and/or] its supplementary material files. Further enquiries can be directed to the corresponding author.
    · The data that support the findings of this study are not publicly available due to [REASON WHY DATA ARE NOT PUBLIC e.g., their containing information that could compromise the privacy of research participants] but are available from [e.g., the corresponding author [author initials] OR Data sharing committee [PROVIDE CONTACT DETAILS including email address] upon reasonable request]
    · The data in this study was obtained from [third party source] where [RESTRICTIONS/LICENCE] may apply. Such a dataset may be requested from [source contact information].


    5) References
    In the text, references should be cited with Arabic numerals in brackets, numbered in the order cited. In the references section, the references should be numbered in order of appearance in the text and listed in English. List all authors if there are less than or equal to six authors. List the first three authors followed by “et al.” if there are more than three authors. If an article has been published online, but has not yet been given an issue or pages, the digital object identifier (DOI) should be supplied. Journal titles should be abbreviated in the style used in Medline. Other types of references not described below should follow Citing Medicine: The NLM Style Guide for Authors, Editors, and Publishers.
    Journal articles:
    1. Yu JI, Park HC, Choi DH, et al. Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiat Oncol J 2016;34:34-44.
    2. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys. 2011 Mar 4 [Epub]. http://dx.doi.org/10.1016/j.ijrobp.2010.11.048.

    Book:
    3. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's clinical oncology. 4th ed. Philadelphia, PA: Churchill Livingstone; 2008.
    4. Jain RK, Kozak KR. Molecular pathophysiology of tumors. In: Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 126-41.

    Conference paper:
    5. Medin PM, Foster RD, von der Kogel, Sayre J, Solberg TD. Spinal cord tolerance to reirradiation with radiosurgery: a swine model. In: 52th ASTRO Annual Meeting; 2010 Oct 31 - Nov 11; San Diego, CA, USA. Farifax, VA: ASTRO; 2010.

    Online sources:
    6. American Cancer Society. Cancer facts & figures [Internet]. Atlanta, GA: American Cancer Society; c2011 [cited 2011 Feb 20]. Available from: http://www.cancer.org/Research/CancerFactsFigures/index.
    7. National Cancer Information Center. Cancer incidence [Internet]. Goyang (KR): National Cancer Information Center; c2011 [cited 2011 Oct 20]. Available from: http://www.cancer.go.kr/cms/statics.

    6) Tables
    Each table should be typed in the separate sheet. The title of the table should be on top-placed, and the first letter of all words (except articles, conjunctions, prepositions) should be capitalized. Tables are numbered in order of citation in the text. Lower case letters in superscripts a), b), c) ... should be used for special remarks. Within a table, if a non-standard abbreviation is used or description may be necessary, then list them under annotation below. The statistical significance of observed differences in the data should be indicated by the appropriate statistical analysis.

    7) Figures
    Upload each figure as a separate image file. The figure images should be provided in PowerPoint file, TIFF, JPEG, GIF, or EPS format with high resolution (preferably 300 dpi for figures and 600 dpi for line art and graph). The figures should be sized to column width (8.5 cm or 17.5 cm). If figures are not original, the author must contact each publisher to request permission, and this should be remarked on the footnote of the figure. Figures should be numbered, using Arabic numerals, in the order in which they are cited. All figures should be cited in the text (e.g., Fig. 1, Fig. 1A-C, Figs. 1 and 2). In the case of multiple prints bearing the same number, use capital letters after the numerals to indicate the correct order (e.g., Fig. 1A, Fig. 1B). A figure legend should be in English and a one-sentence description rather than a phrase or a paragraph. Capitalize the first letter of the first word. A legend for each light microscopic photograph should include the name of stain and magnification. Electron microscopic photographs should have an internal scale marker.
    REVIEWS
    Reviews should be comprehensive analyses of specific topics. They are organized as follows: title page, abstract and keywords, introduction, body text, conclusion, conflicts of interest, acknowledgments (if necessary), references, tables, and figure legends. Upload each figure as a separate image file. There should be an unstructured abstract equal to or less than 200 words. References should be obviously related to documents and should not exceed 50.
    CASE REPORTS
    Case reports will be published only in exceptional circumstances, when they illustrate a rare occurrence of clinical importance. The manuscript for a case report should be organized in the following sequence: title page, abstract and keywords, introduction, case report(s), discussion, conflicts of interest, acknowledgments (if necessary), references, tables, and figure legends. Upload each figure as a separate image file. The abstract should be unstructured, and its length should not exceed 150 words. References should be obviously related to documents and should not exceed 20. It is not necessary to use the word “introduction.”
    EDITORIAL
    Editorials should be commentaries on articles published recently in the journal. Editorial topics could include active areas of research, fresh insights, and debates. Editorials should be no more than four to five pages in length, including references, tables, and figures.
    LETTERS TO THE EDITOR
    Letters to the Editor should include brief constructive comments that concern previously published papers. Letters to the Editor should be no more than two pages. It should have maximum five references, 1 table, and 1 figure. Letters could be edited by the Editorial Board. Responses by the author of the subject paper may be provided in the same issue or next issue of the Journal
    5. COMMUNICATIONS TO THE PUBLISHER
    We invite inquiries to the editorial office at any time during the editorial process. For all matters concerning presubmission, editorial policies, procedures, business inquiries, subscription information, orders, or changes of address, please contact the editorial office.

    Editorial Committee Office
    Department of Radiation Oncology, Seoul National University Hospital,
    Hamchun Hall, 6F, 95 Daehak-ro, Jongno-gu, Seoul 03082, Republic of Korea
    Tel : +82-2-743-6574
    E-mail: rojeditor@gmail.com ,roj@kosro.or.kr
    6. ADDITIONAL INFORMATION
    (1) Copyright
    All published papers become the permanent property of The Korean Society for Radiation Oncology. Upon acceptance of the manuscript, the authors will be required to sign a statement confirming that the manuscript contains no material the publication of which violates any copyright or other personal or proprietary right of any person or entity.

    (2) Page Proofs
    Corresponding authors are provided with page proofs and are asked to carefully review them for data and typesetting errors. When proofs are available, the corresponding author will receive a notification. Corrections to proofs must be returned via e-mail within 48 hours. Publication may be delayed if proofs are not returned by the publisher’s deadline.

    (3) Charges
    There are no charges for submission and publication.

    NOTICE: These recently revised instructions for authors will be applied beginning with the June 2022 issue.
    Copyright¨Ï The Korean Society for Radiation Oncology.
    Hamchun Hall, 6F, 95 Daehak-Ro, Jongno-gu, Seoul, 03082, Republic of Korea
    Tel : +82-2-743-6574   E-mail : roj@kosro.or.kr      Developed in M2PI